Loading stock data…
$1.06-0.01 (-0.93%)
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
Talphera, Inc. in the Healthcare sector is trading at $1.06 with a market capitalization of $62M. Wall Street consensus targets $3.12 (4 analysts), implying a +194.8% move over the next 12 months. The stock is currently 32% below its 52-week high of $1.57, remaining 5.0% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $1,000 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.92M↑ | -$3.95M↓ | -$3.45M↓ | -$3.42M↑ | -$3.69M |
| Net Income | -$4.31M↓ | -$2.56M↑ | -$3.77M↑ | -$4.44M↓ | -$3.49M |
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that a...